1TECH / Bio-Techne Corporation (BIT) - Forecast, Price Target, Estimates, Predictions

Bio-Techne Corporation
IT ˙ BIT ˙ US09073M1045
€45.00 0.00 (0.00%)
2025-09-04
SHARE PRICE
Projected Stock Price
No data available.
Projected Revenue

No data available.
Projected Earnings Per Share

0.67 ↑689.16%

Estimated quarterly earnings by June 30, 2028.

Price Target
No data available.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Bio-Techne Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2025-07-09 TD Cowen Buy Initiate
2025-06-05 Benchmark Buy Buy Reiterate
2025-04-09 Keybanc Overweight Sector Weight Downgrade
2025-04-08 Keybanc Overweight Sector Weight Downgrade
2025-03-18 Evercore ISI Group Outperform Initiate
2025-03-04 Citigroup Neutral Neutral Maintains
2025-02-19 Baird Outperform Neutral Downgrade
2025-02-06 Keybanc Overweight Overweight Maintains
2025-02-06 Scotiabank Sector Outperform Sector Outperform Maintains
2025-02-06 RBC Capital Sector Perform Sector Perform Maintains
2024-10-31 Scotiabank Sector Outperform Sector Outperform Maintains
2024-10-31 Baird Outperform Outperform Maintains
2024-08-13 Benchmark Buy Buy Reiterate
2024-08-08 RBC Capital Sector Perform Sector Perform Maintains
2024-08-08 Baird Outperform Outperform Maintains
2024-05-22 Citigroup Buy Neutral Downgrade
2024-05-02 Benchmark Buy Buy Reiterate
2024-05-02 Baird Outperform Outperform Maintains
2024-04-18 Deutsche Bank Buy Buy Maintains
2024-02-02 RBC Capital Sector Perform Sector Perform Maintains
2024-02-02 Stephens & Co. Overweight Overweight Maintains
2024-02-02 Stifel Buy Hold Downgrade
2023-12-07 UBS Buy Initiate
2023-11-02 Stifel Buy Buy Maintains
2023-11-01 Citigroup Buy Buy Maintains
2023-11-01 RBC Capital Sector Perform Sector Perform Maintains
2023-11-01 Keybanc Overweight Overweight Maintains
2023-09-12 RBC Capital Sector Perform Sector Perform Reiterate
2023-08-28 William Blair Outperform Initiate
2023-08-18 Benchmark Buy Buy Reiterate
2023-08-09 Stephens & Co. Overweight Overweight Reiterate
2023-05-04 Stephens & Co. Overweight Reiterate
2023-05-04 RBC Capital Sector Perform Maintains
2023-05-04 Baird Outperform Maintains
2023-02-06 RBC Capital Sector Perform Maintains
2023-02-03 Benchmark Buy Maintains
2023-02-03 Keybanc Overweight Maintains
2023-02-03 SVB Leerink Outperform Maintains
2023-01-10 Wells Fargo Underweight Equal-Weight Upgrade
2022-12-14 Deutsche Bank Buy Initiate
2022-12-12 Citigroup Neutral Buy Upgrade
2022-12-07 RBC Capital Sector Perform Initiate
2022-12-05 Stephens & Co. Overweight Maintains
2022-11-02 SVB Leerink Outperform Maintains
2022-08-25 Credit Suisse Outperform Initiate
2022-08-16 Wells Fargo Underweight Maintains
2022-08-05 Stephens & Co. Overweight Maintains
2022-05-05 Keybanc Overweight Maintains
2022-04-25 Wells Fargo Equal-Weight Underweight Downgrade
2022-02-02 SVB Leerink Outperform Maintains
2021-09-15 Keybanc Sector Weight Overweight Upgrade
2021-06-29 SVB Leerink Outperform Maintains
2021-06-18 Argus Research Buy Maintains
2021-03-08 Stephens & Co. Equal-Weight Overweight Upgrade
2021-02-23 Stifel Hold Buy Upgrade
2021-02-03 Craig-Hallum Buy Maintains
2021-02-03 Citigroup Neutral Maintains
2020-11-10 KeyBanc Sector Weight Initiate
2020-11-06 SVB Leerink Outperform Maintains
2020-09-30 Atlantic Equities Overweight Initiate
2020-08-05 SVB Leerink Outperform Maintains
2020-07-15 Stephens & Co. Overweight Equal-Weight Downgrade
2020-06-18 Citigroup Neutral Maintains
2020-05-27 Stifel Buy Hold Downgrade
2020-05-14 Benchmark Buy Initiate
2020-05-01 Stephens & Co. Overweight Maintains
2020-05-01 Stifel Buy Maintains
2020-05-01 Wells Fargo Equal-Weight Maintains
2020-04-20 Citigroup Neutral Maintains
2020-04-02 Stifel Buy Maintains
2020-03-30 Wells Fargo Equal-Weight Maintains
2020-03-20 Citigroup Neutral Maintains
2020-02-05 Baird Outperform Maintains
2020-02-05 Citigroup Neutral Maintains
2020-01-08 Wells Fargo Equal-Weight Initiate
2020-01-07 Citigroup Neutral Initiate
2019-11-15 Stifel Nicolaus Buy Initiate
2019-07-02 Janney Capital Neutral Buy Upgrade
2019-01-14 Stephens & Co. Equal-Weight Overweight Upgrade
2018-10-31 Craig-Hallum Buy Hold Downgrade
2018-10-17 Goldman Sachs Neutral Initiate
2018-10-02 Argus Buy Buy Maintains
2018-08-09 Citigroup Buy Buy Maintains
2018-06-27 Deutsche Bank Buy Hold Downgrade
2018-06-15 Argus Buy Initiate
2018-05-03 Deutsche Bank Buy Buy Maintains
2018-03-01 Deutsche Bank Buy Buy Maintains
2018-02-07 Baird Outperform Outperform Maintains
2017-10-24 Citigroup Buy Maintains
2017-08-09 Deutsche Bank Buy Maintains
2017-07-13 Wells Fargo Market Perform Initiate
2017-02-09 Citigroup Buy Initiate
2017-01-18 Deutsche Bank Buy Initiate
2016-08-18 Baird Outperform Maintains
2016-05-03 Janney Capital Neutral Buy Upgrade
2016-02-03 Baird Outperform Maintains
2015-10-29 Stephens & Co. Overweight Equal-Weight Downgrade
2014-04-29 Leerink Swann Market Perform Maintains
2013-09-20 Baird Neutral Outperform Upgrade
2013-08-07 Craig-Hallum Hold Buy Upgrade
2025-05-09 UBS Buy Buy Maintains
2025-08-07 RBC Capital Sector Perform Sector Perform Maintains
2025-05-08 RBC Capital Sector Perform Sector Perform Maintains
2025-05-08 Stifel Hold Hold Maintains
2025-05-08 Benchmark Buy Buy Maintains
2025-05-30 Wells Fargo Overweight Initiate
2025-07-11 Scotiabank Sector Outperform Sector Outperform Maintains
2025-08-21 Citigroup Neutral Buy Upgrade
2025-09-03 RBC Capital Sector Perform Outperform Upgrade
Revenue Estimates
No data available.
Earnings Estimates

The forecasted annual earnings of Bio-Techne Corporation in 2030-06-30 is 2.92 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 0.48 13 -- --
2025-12-31 0.51 13 -- --
2026-03-31 0.60 12 -- --
2026-06-30 0.63 12 2.24 17
2026-09-30 0.52 4 -- --
2026-12-31 0.56 4 -- --
2027-03-31 0.67 4 -- --
2027-06-30 0.71 4 2.57 12
2027-09-30 0.51 3 -- --
2027-12-31 0.57 3 -- --
2028-03-31 0.69 3 -- --
2028-06-30 0.67 3 3.17 3
2029-06-30 -- -- 3.54 3
2030-06-30 -- -- 2.92 3
EBITDA Estimates
No data available.
EBIT Estimates
No data available.
Other Listings
US:TECH $54.41
DE:TE1 €45.00
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista